![Alan M. Garber](/sites/default/files/profile-photos/alan-gerber.png)
Alan M. Garber, MD, PhD
Provost, Harvard University; Mallinckrodt Professor of Health Care Policy, Professor of Economics, Harvard Kennedy School and the Faculty of Arts and Sciences
Harvard Medical SchoolDepartment of Health Care Policy180 Longwood AvenueBoston, MA 02115-5899
Is American health care uniquely inefficient?
Is having more preapproval data the best way to assure drug safety?
Future costs and the future of cost-effectiveness analysis.
A Menu without prices.
Systematic review: the effects of growth hormone on athletic performance.
Authors: Liu H, Bravata DM, Olkin I, et al.
Annals of Internal Medicine
View full abstract on Pubmed
Annals of Internal Medicine
View full abstract on Pubmed
The promise of health care cost-containment
Satisfaction guaranteed - “payment by results” for biologic agents
Essential elements of a technology and outcomes assessment initiative.
Authors: Emanuel EJ, Fuchs VR and Garber AM
Journal of the American Medical Association
View full abstract on Pubmed
Journal of the American Medical Association
View full abstract on Pubmed
Influence of race on inpatient treatment intensity at the end of life
Authors: Barnato AE, Chang CC, Saynina O, et al.
Journal of General Internal Medicine
View full abstract on Pubmed
Journal of General Internal Medicine
View full abstract on Pubmed
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER-2/neu-positive breast cancer.
Authors: Kurian AW, Newton Thompson R, Gaw AF, et al.
Journal of Clinical Oncology
View full abstract on Pubmed
Journal of Clinical Oncology
View full abstract on Pubmed